Abstract
[Vaccins contre lwe coronavirus] .
The present invention provides multimeric protein complex comprising three polypeptides each comprising N- to C -terminally: (i) a receptor-binding domain (RBD) of an S1 subunit of an S protein of a coronavirus, (ii) optionally a S2 subunit of an S protein of a coronavirus; and (iii) a multimerization domain comprising a collagen-like region (CLR) of ficolin-2, wherein the multimerization domain enables the assembly of the polypeptides into a multimeric protein complex. The present invention further provides polynucleotides encoding the polypeptides of the multimeric protein complex, expression vectors, pharmaceutical compositions and uses of the multimeric protein complexes, such as a vaccine.
The present invention provides multimeric protein complex comprising three polypeptides each comprising N- to C -terminally: (i) a receptor-binding domain (RBD) of an S1 subunit of an S protein of a coronavirus, (ii) optionally a S2 subunit of an S protein of a coronavirus; and (iii) a multimerization domain comprising a collagen-like region (CLR) of ficolin-2, wherein the multimerization domain enables the assembly of the polypeptides into a multimeric protein complex. The present invention further provides polynucleotides encoding the polypeptides of the multimeric protein complex, expression vectors, pharmaceutical compositions and uses of the multimeric protein complexes, such as a vaccine.
| Original language | English |
|---|---|
| Patent number | WO2023280998A1 |
| IPC | A61K39/12; A61P31/14; C07K14/78; |
| Priority date | 7/07/21 |
| Publication status | Published - 12 Jan 2023 |